Overview

Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetic (PK) of GDC-0349 administered once daily (QD), orally (PO).
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.